GlycoMimetics Initiates Clinical Trial Evaluating Uproleselan In Combination With Venetoclax And Azacitidine
GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that clinicians at University of California (UC) Davis Comprehensive Cancer Center initiated dosing of the first patient in a clinical study of uproleselan combined with